AstraZeneca's heart disease silencer fails Phase 3, raising doubts about injectable approach

AstraZeneca announced that its Phase 3 trial of a silencer drug for transthyretin amyloid cardiomyopathy failed to demonstrate any advantage over existing therapy. Patients enrolled in the study were largely receiving an oral stabilizer, and the silencer did not produce further improvement, leading to the trial’s termination. The outcome impacts AstraZeneca’s collaboration with Ionis Pharmaceuticals and casts doubt on the injectable silencer strategy across the market.

Competitors Alnylam Pharmaceuticals, which sells another silencer, and BridgeBio, the maker of a new stabilizer, are also affected by the findings. Analysts suggest the results may tip the balance toward oral stabilizers as the preferred treatment option for this multi-billion-dollar disease area.